A major shift is unfolding in global cannabis policy—and it’s coming from one of the most medically advanced cannabis markets in the world. According to recent developments reported by The Times of Israel, a health ministry panel in Israel is advising a halt to smoking medical cannabis, while actively supporting alternative delivery methods. At the core of the recommendation is a clinical concern: smoking cannabis, even in a medical context, is difficult to standardize. Dosing becomes inconsistent, absorption varies from patient to patient, and long-term respiratory risks remain difficult to quantify. Israeli regulators are now moving toward a pharmaceutical-style framework—where cannabis is treated less like a plant and more like a controlled therapeutic compound. The data driving this shift is significant. Medical cannabis use in Israel has surged dramatically in recent years, with a sharp increase in high-THC consumption and a majority of patients relying on smokable formats. This raised concerns among policymakers about dependency risks, lack of dosage control, and the broader public health implications of widespread smoking as a “medical” method. The proposed solution is not prohibition—but evolution. Regulators are advocating for alternatives such as vaporizers, inhalers, oils, and extracts that allow for more precise dosing and medical oversight. In fact, smoking could be phased out entirely over the next few years, with exceptions only in rare, medically justified cases. This is where the conversation becomes bigger than Israel. What we’re seeing is a global pivot: cannabis is being pulled deeper into the healthcare system. Prescription-based models, tighter monitoring, and standardized formats are becoming the new benchmark. The shift reflects a broader question—should cannabis remain a lifestyle product, or fully transition into a regulated medical treatment? For markets like New York, this signals what’s coming next. As legalization matures, expect increased scrutiny on how cannabis is consumed—not just whether it’s legal. Delivery methods, potency, and patient tracking will likely become central to future regulation. At Elevated Club NYC, this reinforces a simple principle: evolution is part of elevation. As the industry advances, so does the expectation for quality, consistency, and informed use. Whether through flower, concentrates, or alternative formats, the future of cannabis will be defined by how precisely it can meet individual needs. The takeaway is clear—cannabis isn’t moving backward. It’s moving toward structure, science, and a more refined experience.

A new shift in federal cannabis policy is sending mixed signals across the industry. According to recent reporting from The New York Times DealBook, the current administration’s approach to cannabis reform is less of a clean breakthrough—and more of a strategic, fragmented recalibration. At the center of the conversation is the move to reclassify cannabis from a Schedule I substance to Schedule III—but only in limited contexts. Specifically, state-licensed medical cannabis and future FDA-approved cannabinoid products are being repositioned under a less restrictive classification. This signals a federal acknowledgment of cannabis’ medical utility, a significant departure from decades of strict prohibition. But the reality is more complex. This isn’t full legalization. It’s not even full rescheduling. It’s a partial shift—one that creates a split system between medical and recreational markets. Adult-use cannabis remains federally illegal, meaning businesses operating in that space continue to face tax burdens, banking limitations, and regulatory uncertainty. For operators, this creates a two-lane industry. Medical cannabis could benefit from improved research access, tax relief, and federal legitimacy. Meanwhile, the broader recreational market—the dominant revenue driver in states like New York—remains locked in a gray zone. From a business standpoint, this dual structure introduces both opportunity and risk. On one hand, institutional investment may increase as cannabis gains credibility within federal frameworks. On the other, the lack of clarity could widen the gap between compliant medical operators and independent delivery-based or adult-use services. There’s also a deeper economic layer. Federal rescheduling could eliminate the IRS 280E tax penalty for certain operators, allowing them to deduct standard business expenses. That alone has the potential to reshape margins across the industry. Still, the rollout has been described as inconsistent. Analysts and industry leaders note that without unified federal reform—including banking access and interstate commerce—the cannabis economy remains structurally constrained. For New York, this matters. The city operates at the intersection of legality, culture, and demand. Consumers aren’t waiting for federal alignment—they’re already participating in a mature, fast-moving market. What federal policy does now is shape how that market evolves: more institutional, more regulated, and potentially more competitive. The takeaway is clear—this is progress, but not resolution. The cannabis industry isn’t being fully unlocked. It’s being repositioned, piece by piece. And in a city like New York, where speed defines relevance, those shifts will determine who scales—and who gets left behind.

A new study highlighted by ScienceDaily is forcing the cannabis industry—and consumers—to rethink one of the most overlooked parts of the plant: the leaves. For years, cannabis culture has been centered around flower. Leaves were often treated as waste—discarded, trimmed away, or used minimally. But new research out of Stellenbosch University suggests that assumption may have been a major oversight. Scientists identified 79 phenolic compounds in cannabis samples, including 25 that had never been documented before. Even more notable, researchers found evidence of flavoalkaloids—a rare class of compounds never before detected in cannabis. Why does that matter? Because phenolic compounds—especially flavonoids—are already associated with anti-inflammatory, antioxidant, and potential anti-cancer properties. The discovery of flavoalkaloids suggests cannabis may hold an even deeper biochemical profile than previously understood. What stands out most is where these compounds were found: primarily in the leaves, not the flower. That single detail flips traditional cannabis hierarchy on its head. From a market perspective, this opens new lanes. Leaves could shift from low-value byproduct to high-value extraction material, especially in wellness, pharmaceutical, and functional product development. Think tinctures, topicals, and next-generation formulations built around compounds most consumers have never heard of—yet. It also reinforces something the industry is slowly realizing: cannabis isn’t just THC vs CBD. It’s a complex chemical system where minor compounds—often ignored—may drive future innovation. For brands and operators, the takeaway is strategic. As research deepens, differentiation will come less from potency and more from composition, sourcing, and full-plant utilization. For consumers, it’s a reminder: what you’ve been told is “the best part” of the plant may only be part of the story. Cannabis is still revealing itself—and this study makes one thing clear: we’re nowhere near the ceiling of what this plant can offer.

The cannabis industry continues to evolve—but so does federal enforcement. In a recent clarification, the Drug Enforcement Administration (DEA) confirmed that HHC (hexahydrocannabinol), a widely marketed cannabinoid, is federally illegal and does not qualify as hemp under current law. This move cuts directly into one of the most controversial gray areas in cannabis: synthetic cannabinoids derived from hemp. For years, products like HHC, delta-8, and other chemically altered compounds have been sold under the assumption that they fall within the protections of the 2018 Farm Bill. That legislation legalized hemp—defined as cannabis containing less than 0.3% delta-9 THC—but left room for interpretation when it came to cannabinoids created through chemical conversion. The DEA is now removing that ambiguity. According to the agency, only cannabinoids that are naturally occurring in the cannabis plant qualify as legal hemp derivatives. Any compound—like HHC—that is produced through chemical processes, even if sourced from hemp, is considered synthetically derived and therefore remains a Schedule I controlled substance under the Controlled Substances Act. This distinction is critical. It signals that federal regulators are no longer tolerating the “hemp loophole” that allowed intoxicating products to flood the market outside of traditional cannabis regulations. From a business standpoint, the implications are immediate. Retailers, brands, and distributors dealing in HHC products now face heightened legal exposure. Inventory once marketed as compliant could now fall squarely under federal prohibition. More broadly, this decision aligns with upcoming federal changes. New legislation scheduled for full enforcement in late 2026 is expected to tighten the definition of hemp even further—targeting synthetic and intoxicating cannabinoids across the board. In other words, this isn’t an isolated clarification—it’s part of a larger regulatory shift. For consumers, the takeaway is simple: not everything labeled “hemp” is federally legal. The line between compliant and controlled substances is being redrawn in real time. For the culture, it reinforces something deeper: authentic cannabis—plant-derived, regulated, and transparent—is where the market is heading. At Elevated Club NYC, that distinction matters.

California voters are facing a new ballot measure that directly targets one of the biggest ongoing issues in the cannabis industry: the illegal market. The proposed measure—often referred to as Measure CB—focuses on increasing penalties and introducing new tax mechanisms aimed at unlicensed cannabis operations. On the surface, it’s positioned as a solution to protect legal businesses. But the reality is more complex. California already has one of the largest legal cannabis markets in the world, yet illegal sales continue to dominate significant portions of the state. High taxes, strict regulations, and costly compliance requirements have made it difficult for licensed operators to compete. This measure attempts to correct that imbalance by cracking down harder on illicit activity while redirecting funds through enforcement and taxation. Supporters argue that stronger enforcement is necessary. Legal operators are paying state and local taxes, following regulations, and investing in testing and safety standards—while illegal sellers operate without those costs. The measure is designed to level that playing field by making it more expensive and riskier to operate outside the legal system. However, critics point out a key issue: enforcement alone may not solve the problem. California’s cannabis taxes are already among the highest in the country. Increasing financial pressure without reducing existing tax burdens could further strain the legal market. Some industry voices suggest that lowering taxes and simplifying licensing would be a more effective long-term strategy than expanding penalties. There are also concerns about how enforcement is applied. Historically, aggressive crackdowns have disproportionately impacted smaller operators and marginalized communities—many of whom were excluded from early legalization opportunities. Without careful oversight, the measure risks repeating those patterns instead of correcting them. For consumers, the stakes are indirect but significant. A stronger legal market could mean better product consistency, safety, and accessibility. But if prices remain high due to taxes, many consumers may continue to turn to the unregulated market, keeping the cycle in place. The broader takeaway is this: California is still trying to find balance. Legalization alone didn’t eliminate the illegal market—it reshaped it. Measures like this show that the industry is still evolving, with policymakers experimenting in real time. Whether this approach strengthens the legal market or adds new pressure will depend on how it’s implemented—and whether deeper structural issues like taxation are addressed alongside enforcement. Education is elevation.

A new federal shift on cannabis is making headlines—but not for the clarity people were hoping for. The Trump administration has initiated what’s being called a “rescheduling” of cannabis, moving certain products from Schedule I to Schedule III. On paper, that sounds like progress. In reality, it’s a partial move that introduces more questions than answers. Here’s the breakdown: only cannabis tied to state-licensed medical programs—and certain future FDA-approved cannabis drugs—are included in this shift. That means the broader cannabis market, especially adult-use and recreational systems, remains untouched at the federal level. Cat Packer and other policy analysts have emphasized that this is not full rescheduling, but a limited and highly specific adjustment. The result is a split system. Medical cannabis may see reduced federal restrictions, potential tax relief, and expanded research pathways. But outside that lane, cannabis is still treated as federally illegal. For operators, consumers, and regulators, that creates a fragmented landscape where legality depends heavily on how a product is categorized—not just what it is. There are also equity concerns. Because the new framework centers on medical licensing, businesses operating in adult-use markets—many of which include minority entrepreneurs—could be left behind. The policy risks reinforcing existing disparities rather than correcting them, especially given the historical barriers to entering early medical programs. For consumers, the immediate impact is minimal. This doesn’t legalize cannabis nationwide. It doesn’t erase federal penalties. And it doesn’t simplify access across state lines. What it does signal, however, is a shift in federal acknowledgment: cannabis has recognized medical value—but the system governing it is still evolving. A key next step is a DEA hearing scheduled for late June, where broader rescheduling could be debated. But even that outcome is uncertain. Full federal legalization remains a separate—and far more complex—conversation. Bottom line: this isn’t the finish line. It’s a technical adjustment in a much larger regulatory transition. The industry is moving forward—but not in a straight line. Education is elevation.

Indiana may still have some of the strictest cannabis laws in the country, but the numbers tell a completely different story. A new statewide study reveals that residents are already spending over $1 billion annually on cannabis, despite the plant remaining largely illegal within state lines. This isn’t just a statistic—it’s a signal. Demand is already established, deeply rooted, and growing. According to the report, adult cannabis use in Indiana has steadily increased over the past decade. What’s even more telling is accessibility. Nearly half of Indiana residents live within a 50-mile drive of a legal dispensary, thanks to neighboring states like Illinois, Michigan, and Ohio embracing full legalization. Translation: the market exists—it’s just happening across state borders. This is a familiar pattern across the U.S. When legislation lags behind consumer behavior, the economy doesn’t stop—it reroutes. Indiana consumers are simply taking their dollars elsewhere, fueling legal markets in surrounding states while their own state misses out on tax revenue, job creation, and regulatory control. And the potential is massive. Studies suggest legalization could unlock significant state revenue while reducing enforcement costs tied to outdated cannabis laws. Meanwhile, public support continues to climb, signaling a shift not just in consumption—but in perception. From a business and cultural standpoint, Indiana represents a textbook example of a “shadow market” transitioning toward inevitability. The infrastructure is already there: consumer demand, regional supply chains, and normalized access. The only missing piece is policy alignment. At Elevated Club NYC, we watch these developments closely because they reflect a broader national trend. Cannabis isn’t waiting for permission anymore—it’s integrating into everyday life, state by state, consumer by consumer. The takeaway is simple: prohibition doesn’t erase demand—it just relocates opportunity. As more states modernize their approach, the gap between legislation and reality becomes harder to ignore. Indiana may not be fully there yet, but the data makes one thing clear—the market has already arrived. Education is elevation. — Justice, Elevated Club NYC

The cannabis conversation in America is evolving fast—but in Texas, it’s turning into a legal battle with national implications. A group of hemp businesses has filed a lawsuit against the state, challenging new regulations that they say could effectively dismantle the legal hemp market. At the center of the issue is how Texas defines THC. Since 2019, hemp has been federally and state-legal if it contains less than 0.3% Delta-9 THC. But new rules introduced by Texas regulators expand that definition by factoring in compounds like THCA—an inactive cannabinoid that converts into Delta-9 when heated. That shift may sound technical, but the impact is massive. By using a “total THC” calculation, the state has effectively banned the sale of smokable hemp products like flower and concentrates—items that make up the majority of the market. Economists estimate smokable products represent up to two-thirds of all hemp sales in Texas, meaning thousands of businesses could be affected overnight. The lawsuit argues that regulators overstepped their authority, replacing legislative definitions with agency-made rules. It also challenges steep licensing increases—jumping from a few hundred dollars to as much as $10,000 annually for manufacturers and $5,000 per retail location. For small operators, those costs aren’t just regulatory—they’re existential. There’s also a deeper concern: unintended consequences. Industry leaders warn that eliminating legal access doesn’t eliminate demand—it shifts it. When regulated products disappear, unregulated markets tend to fill the gap, often without safety testing, labeling, or consumer protections. In a temporary twist, a Texas judge has already stepped in, blocking parts of the rule—specifically the ban on smokable hemp—while the case moves forward. That pause gives businesses breathing room, but the long-term outcome remains uncertain. For the broader cannabis industry, this case highlights a critical tension: regulation vs. prohibition disguised as policy. As states continue to refine cannabis laws, how they define compounds like THC will determine what remains legal—and what disappears. At Elevated Club NYC, we’re watching closely. Because what happens in Texas doesn’t stay in Texas—it shapes the future of cannabis nationwide. Education is elevation. — Justice, Elevated Club NYC

Cannabis culture continues to evolve at a rapid pace, and one of the clearest signals of that momentum is the surge in sales seen around 4/20—an annual moment that has transformed from a counterculture celebration into a major economic driver for the industry. Recent data shows that cannabis retailers across the country experienced a significant spike in sales during this year’s 4/20, driven by a combination of aggressive promotions, increased consumer normalization, and a more educated customer base that understands product quality and value. What was once an underground holiday is now a fully integrated retail event, comparable to Black Friday in structure and impact. Dispensaries leaned into limited-time offers, bundle pricing, and exclusive drops, creating urgency and driving higher basket sizes, while consumers responded with strong engagement, stocking up on flower, pre-rolls, edibles, and vapes. Beyond the numbers, the spike reflects something deeper: cannabis is no longer niche—it’s mainstream, and it’s being treated like any other consumer category with seasonal demand cycles and strategic marketing windows. At Elevated Club NYC, this aligns directly with how we approach the market—focusing on accessibility, consistency, and a curated experience that removes friction from the process. No storefront, no lines, no stress—just a seamless delivery model built for the city. As demand continues to rise during key cultural moments like 4/20, it reinforces the importance of infrastructure, logistics, and brand trust in meeting customer expectations. The takeaway is clear: cannabis isn’t just growing, it’s maturing into a structured, high-performing retail ecosystem. And as the industry continues to scale, moments like 4/20 will only become more refined, more competitive, and more impactful for both consumers and operators.

A major step forward for cannabis reform just landed in Maryland — and it’s one that signals where the broader national conversation is heading. On April 28, 2026, Governor Wes Moore signed legislation protecting firefighters and other rescue workers from employment discrimination tied to off-duty medical cannabis use. The law ensures that registered medical cannabis patients working in fire and rescue roles cannot be disciplined, fired, or penalized solely for testing positive for cannabis metabolites — a long-standing issue due to how cannabis lingers in the body far beyond impairment. This is a critical distinction. For years, first responders have faced a contradiction: access to legal medical cannabis on paper, but real-world consequences in the workplace. Unlike alcohol or prescription medications, cannabis testing has often failed to measure actual impairment — instead detecting past use, sometimes weeks after consumption. Maryland’s new law directly addresses that gap. It applies broadly to firefighters, EMTs, paramedics, and other rescue personnel employed at the state or local level. More importantly, it establishes a clear standard: off-duty, state-authorized medical cannabis use is not grounds for workplace punishment. At the same time, the legislation draws a firm line on safety. Employers still retain the authority to act if a worker is impaired on duty — reinforcing that this isn’t about relaxing standards, but modernizing them. Why does this matter? Because first responders operate under extreme physical and psychological stress. Chronic pain, PTSD, and injury are not exceptions — they’re part of the job. Many have historically relied on opioids or other pharmaceuticals to cope, often with long-term consequences. Cannabis offers an alternative, but until now, using it legally could still cost someone their career. That’s the barrier Maryland just removed. From a broader perspective, this move reflects a deeper shift in how cannabis is being integrated into professional life. It’s no longer just about legalization — it’s about normalization within regulated systems, including employment law. We’re seeing a transition from outdated zero-tolerance frameworks to policies that distinguish between use and impairment, which is how most other substances are treated. For the industry, this is another signal: cannabis is continuing to align with mainstream standards of medicine, labor rights, and workplace fairness. And for cities like New York — where conversations around cannabis, public safety, and workforce protections are still evolving — this type of legislation offers a blueprint. The takeaway is simple: Policy is catching up to reality. As more states adopt similar protections, the expectation around cannabis — especially medical use — will continue to shift from stigma to structure. Education is elevation. — Justice, Elevated Club NYC

USA Today recently spotlighted a growing contradiction shaping the cannabis industry: while federal policy is moving toward acceptance, concerns around potency are becoming louder than ever. The current shift—driven under Donald Trump’s administration—aims to reclassify cannabis from Schedule I to Schedule III. On paper, that’s a major evolution. It acknowledges medical use, reduces regulatory pressure, and opens the door for expanded research. For operators, it could mean relief from burdensome tax structures and a more stable framework. But the conversation doesn’t end there. The article raises a critical point: today’s cannabis is not what it was decades ago. THC levels have increased significantly, and with that comes a new layer of scrutiny. The concern isn’t legalization itself—it’s whether regulation is evolving fast enough to match product strength. This is where the industry sits right now—between progress and pressure. On one side, rescheduling signals legitimacy. It aligns federal thinking closer to the reality on the ground, where most states already operate legal or medical markets. It reinforces the idea that cannabis belongs in a regulated system, not in the shadows. On the other side, rising potency introduces real questions. Public health voices are pushing for tighter oversight, clearer labeling, and more consumer education. The fear is that without those controls, perception could outpace responsibility. For New York, this tension is already visible. Recent enforcement actions—like the shutdown of illicit smoke shops—show the state is serious about structure. At the same time, federal policy is becoming more flexible. That push and pull is defining the next phase of the market: stricter enforcement paired with broader legitimacy. For consumers, the takeaway is simple but important—not all cannabis experiences are equal. Potency, sourcing, and compliance matter more now than ever. As the market matures, the gap between regulated and unregulated product becomes more than legal—it becomes qualitative. At Elevated Club NYC, the focus stays aligned with where the industry is heading: standards, consistency, and awareness. The conversation around cannabis is evolving beyond access—it’s moving toward accountability. Because the future of cannabis in New York isn’t just about availability. It’s about getting it right.

New York’s cannabis market continues to evolve—and with it, enforcement is ramping up in a serious way. A recent operation in Rochester highlights exactly where the state stands right now: protecting the legal market while aggressively targeting unlicensed operators. Authorities shut down two smoke shops following a long-term investigation into illegal cannabis sales. The enforcement effort, led by the New York State Office of Cannabis Management in collaboration with local law enforcement, resulted in the seizure of more than $1.3 million worth of cannabis products. What was found inside paints a clear picture of scale. Officials recovered over 147 pounds of flower, thousands of vape devices, more than 5,000 edible packages, and nearly 2,000 pre-rolls—all allegedly being sold outside of New York’s licensed system. Both locations were immediately padlocked and issued orders to cease operations. But this situation goes deeper than just a shutdown—it’s part of a broader strategy. New York has made it clear: the legal cannabis industry is built on compliance, testing, and accountability. When unlicensed shops bypass those systems, it creates multiple problems. First, there’s consumer safety. Products sold through illicit channels aren’t subject to the same testing standards, meaning potency, contaminants, and sourcing remain unknown. Second, there’s market integrity. Licensed operators invest heavily into compliance, taxes, and quality control. Illegal shops undercut that structure, pulling revenue away from a system designed to reinvest into communities. This latest enforcement action also shows how investigations are evolving. Officials noted that many cases begin with public complaints, then develop into long-term operations to gather proof before executing raids and seizures. For the broader industry, the message is direct: New York is no longer in a passive phase. The state is actively identifying, investigating, and shutting down illicit operations at scale—and Rochester is just one example of that momentum. For consumers, this moment reinforces something important—where you shop matters. Verified, compliant sources aren’t just about legality; they’re about consistency, transparency, and safety. At Elevated Club NYC, that philosophy stays central. The future of cannabis in New York isn’t built on shortcuts—it’s built on standards.